Ironwood Pharma (IRWD) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
February 15, 2018 8:01 AM ESTGenerated 2017 revenue of $298 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61%
On track to advance key pipeline candidates in 2018, including Phase III trials for IW-3718 and LINZESS and Phase II trials for praliciguat (IW-1973) and IW-1701
Expect to generate positive cash flow in 4Q 2018 through continued top-line growth and financial discipline
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
